Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference

a proof-of-concept study

Thomas Geisbert, Amy CH Lee, Marjorie Robbins, Joan B. Geisbert, Anna N. Honko, Vandana Sood, Joshua C. Johnson, Susan de Jong, Iran Tavakoli, Adam Judge, Lisa E. Hensley, Ian MacLachlan

Research output: Contribution to journalArticle

332 Citations (Scopus)

Abstract

Background: We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever. Methods: A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV. Findings: Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection. Interpretation: This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections. Funding: Defense Threat Reduction Agency.

Original languageEnglish (US)
Pages (from-to)1896-1905
Number of pages10
JournalThe Lancet
Volume375
Issue number9729
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Ebolavirus
RNA Interference
Primates
Small Interfering RNA
Ebola Hemorrhagic Fever
Macaca
Virus Diseases
Nucleic Acids
Therapeutics
Lipids
Viral Proteins
DNA-Directed RNA Polymerases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference : a proof-of-concept study. / Geisbert, Thomas; Lee, Amy CH; Robbins, Marjorie; Geisbert, Joan B.; Honko, Anna N.; Sood, Vandana; Johnson, Joshua C.; de Jong, Susan; Tavakoli, Iran; Judge, Adam; Hensley, Lisa E.; MacLachlan, Ian.

In: The Lancet, Vol. 375, No. 9729, 2010, p. 1896-1905.

Research output: Contribution to journalArticle

Geisbert, T, Lee, ACH, Robbins, M, Geisbert, JB, Honko, AN, Sood, V, Johnson, JC, de Jong, S, Tavakoli, I, Judge, A, Hensley, LE & MacLachlan, I 2010, 'Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study', The Lancet, vol. 375, no. 9729, pp. 1896-1905. https://doi.org/10.1016/S0140-6736(10)60357-1
Geisbert, Thomas ; Lee, Amy CH ; Robbins, Marjorie ; Geisbert, Joan B. ; Honko, Anna N. ; Sood, Vandana ; Johnson, Joshua C. ; de Jong, Susan ; Tavakoli, Iran ; Judge, Adam ; Hensley, Lisa E. ; MacLachlan, Ian. / Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference : a proof-of-concept study. In: The Lancet. 2010 ; Vol. 375, No. 9729. pp. 1896-1905.
@article{68eff81b65334d51adb78dc97f56d2db,
title = "Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study",
abstract = "Background: We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever. Methods: A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV. Findings: Two (66{\%}) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection. Interpretation: This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections. Funding: Defense Threat Reduction Agency.",
author = "Thomas Geisbert and Lee, {Amy CH} and Marjorie Robbins and Geisbert, {Joan B.} and Honko, {Anna N.} and Vandana Sood and Johnson, {Joshua C.} and {de Jong}, Susan and Iran Tavakoli and Adam Judge and Hensley, {Lisa E.} and Ian MacLachlan",
year = "2010",
doi = "10.1016/S0140-6736(10)60357-1",
language = "English (US)",
volume = "375",
pages = "1896--1905",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9729",

}

TY - JOUR

T1 - Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference

T2 - a proof-of-concept study

AU - Geisbert, Thomas

AU - Lee, Amy CH

AU - Robbins, Marjorie

AU - Geisbert, Joan B.

AU - Honko, Anna N.

AU - Sood, Vandana

AU - Johnson, Joshua C.

AU - de Jong, Susan

AU - Tavakoli, Iran

AU - Judge, Adam

AU - Hensley, Lisa E.

AU - MacLachlan, Ian

PY - 2010

Y1 - 2010

N2 - Background: We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever. Methods: A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV. Findings: Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection. Interpretation: This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections. Funding: Defense Threat Reduction Agency.

AB - Background: We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever. Methods: A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV. Findings: Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection. Interpretation: This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections. Funding: Defense Threat Reduction Agency.

UR - http://www.scopus.com/inward/record.url?scp=77952680862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952680862&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60357-1

DO - 10.1016/S0140-6736(10)60357-1

M3 - Article

VL - 375

SP - 1896

EP - 1905

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9729

ER -